Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
Older
May 23, 2024
Trading Halt
May 16, 2024
Neuren CEO to present at BIO & Jefferies conferences in US
May 15, 2024
Investor presentation, 15 May 2024
May 09, 2024
DAYBUE Q1 net sales US$75.9m, full-year guidance US$370-420m
May 07, 2024
Notification of cessation of securities - NEU
Apr 26, 2024
Notification of cessation of securities - NEU
Apr 26, 2024
Virtual AGM online guide
Apr 26, 2024
Notice of Annual General Meeting/Proxy Form
Apr 24, 2024
Q1 2024 quarterly activity and cash flow report
Apr 23, 2024
Trofinetide accepted for Priority Review by Health Canada
Previous
1
2
3
4
5
Next
